RIPK1 and breast carcinoma: For experimental validation of the transcriptome results, and also to test whether modulation of ZNF611, ZNF304, RIPK1, DUSP8, HRAS and TNFRS21 following knockdown of miR‐122 might be a common event in radioresistant breast cancer cells, we performed western blot assays in transfected MCF‐7RR and MDA‐MB‐231RR cells with antagomiR‐122.